Douglas Lane & Associates LLC Lowers Stake in GSK PLC Sponsored ADR $GSK

Douglas Lane & Associates LLC reduced its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 20.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 749,690 shares of the pharmaceutical company’s stock after selling 196,946 shares during the period. Douglas Lane & Associates LLC’s holdings in GSK were worth $36,113,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in GSK. Bogart Wealth LLC boosted its stake in shares of GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after acquiring an additional 200 shares during the last quarter. Natural Investments LLC increased its stake in shares of GSK by 2.8% in the 2nd quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company’s stock worth $405,000 after purchasing an additional 211 shares in the last quarter. Grove Bank & Trust increased its stake in shares of GSK by 3.8% in the 3rd quarter. Grove Bank & Trust now owns 5,859 shares of the pharmaceutical company’s stock worth $282,000 after purchasing an additional 215 shares in the last quarter. Canandaigua National Bank & Trust Co. raised its holdings in GSK by 3.7% in the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 6,185 shares of the pharmaceutical company’s stock worth $298,000 after purchasing an additional 223 shares during the period. Finally, HF Advisory Group LLC raised its holdings in GSK by 3.5% in the 2nd quarter. HF Advisory Group LLC now owns 7,578 shares of the pharmaceutical company’s stock worth $397,000 after purchasing an additional 259 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Berenberg Bank set a $60.00 price target on GSK in a report on Tuesday, September 15th. Weiss Ratings downgraded GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research report on Thursday, July 30th. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, HSBC reissued a “hold” rating on shares of GSK in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $61.00.

GSK Price Performance

NYSE:GSK traded up $0.09 on Friday, reaching $46.62. 5,658,264 shares of the company’s stock traded hands, compared to its average volume of 4,412,995. The stock has a 50-day simple moving average of $50.12 and a 200-day simple moving average of $51.87. GSK PLC Sponsored ADR has a 12 month low of $42.85 and a 12 month high of $61.69. The firm has a market cap of $94.31 billion, a PE ratio of 14.58, a P/E/G ratio of 2.11 and a beta of 0.33. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81.

GSK (NYSE:GSK) last released its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts forecast that GSK PLC Sponsored ADR will post 4.79 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a $0.4515 dividend. This represents a $1.81 annualized dividend and a yield of 3.9%. The ex-dividend date was Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio is currently 55.31%.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.